Aigen Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Aigen Investment Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-39,302	Closed	-$2.12M	–	539
2025 Q4	$2.12M	Sell	39,302 -1,476	-4%	-$71K	0.49%	46
2025 Q3	$1.84M	Buy	+40,778	New	+$1.9M	0.28%	79
2024 Q4	–	Sell	-22,885	Closed	-$1.18M	–	744
2024 Q3	$1.18M	Sell	22,885 -102,823	-82%	-$4.82M	0.23%	121
2024 Q2	$5.22M	Buy	125,708 +109,757	+688%	+$4.91M	1.02%	2
2024 Q1	$865K	Buy	+15,951	New	+$813K	0.19%	168
2023 Q1	–	Sell	-41,754	Closed	-$3M	–	626
2022 Q4	$3M	Buy	+41,754	New	+$3.15M	0.43%	62
2022 Q1	–	Sell	-32,921	Closed	-$1.91M	–	592
2021 Q4	$1.91M	Buy	+32,921	New	+$1.93M	0.12%	228
2021 Q3	–	Sell	-22,982	Closed	-$1.54M	–	479
2021 Q2	$1.54M	Sell	22,982 -1,886	-8%	-$123K	0.27%	104
2021 Q1	$1.57M	Buy	+24,868	New	+$1.55M	0.21%	118
2020 Q2	–	Sell	-25,412	Closed	-$1.42M	–	849
2020 Q1	$1.42M	Buy	+25,412	New	+$1.55M	0.19%	145

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aigen Investment Management's BMY Position: Q1 2026 in Review

Aigen Investment Management sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 39,302 shares — an estimated $2.12M sold.

Aigen Investment Management first reported a position in BMY in Q1 2020 and held it in 10 quarters. The position peaked at $5.22M in Q2 2024. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Aigen Investment Management reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
Aigen Investment Management sold 39,302 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.12M.
Aigen Investment Management first reported a position in Bristol-Myers Squibb in Q1 2020 and held it in 10 quarters.
Aigen Investment Management's Bristol-Myers Squibb position peaked at $5.22M in Q2 2024.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.